Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > National Bank On Th

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jan 05, 2023 5:49pm

155 Views

Post# 35205719

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:National Bank On Th

I agree ---- It puzxkes me why this was brought up!!!
Most drugs have all kinds of possible side effects even if very very very unlikely
Even Luthatera can cause cancer according to

scarlet1967 wrote:
“Cancer risk

In theory, there is a risk that use of tesamorelin—because it stimulates the release of growth hormone, which can drive the growth of cancer cells—may increase the risk for cancer. However, rates of cancer were low and similar among recipients of tesamorelin and placebo. Moreover, there was only one case of cancer among tesamorelin users where doctors suspected that this drug may have contributed to the growth of cancer (Hodgkin’s disease). A similar case of cancer also occurred in a person who received placebo.”

Nothing to be concerned about!

https://www.catie.ca/treatmentupdate-182/tesamorelin-overview#:~:text=Cancer%20risk,recipients%20of%20tesamorelin%20and%20placebo.